1544. Location of Care and Ceftaroline Fosamil Use for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-acquired Bacterial Pneumonia (CABP): CAPTURE Study Experience
Session: Poster Abstract Session: Clinical Infectious Diseases: Soft Tissue Infections (ABSSSIs)
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • LOC_ABSSSI-CABP[F1.00].pdf (541.2 kB)
  • Background: Ceftaroline fosamil (CPT-F) is approved for the treatment of ABSSSI and CABP in the US. CAPTURE is a multicenter retrospective study evaluating patients (pts) treated with CPT-F in the US. We compared data by location of care (LOC) for pts treated with CPT-F for these indications.

    Methods: Data were collected by review of randomly ordered patient charts between Aug 2011 and Feb 2015, and included demographics, medical history, disease characteristics, antibiotic use, LOC, pathogens isolated and clinical response. Clinical success in pts was defined as clinical cure with no further need for antibiotic therapy, or clinical improvement with a switch to oral antibiotic therapy at the end of CPT-F treatment.

    Results: Of 3194 evaluable pts, 1982 (62%) were treated for ABSSSI, and 811 (25%) for CABP. Among ABSSSI pts mean age was 59 ± 18 years; 1087 (55%) were male; 997 (50%) had comorbidities, most commonly diabetes 872 (44%) and peripheral vascular disease (PVD) 279 (14%). Most common infection type was deep/extensive cellulitis 1305 (66%); and site of infection, leg/thigh 994 (50%). 1530 (77%) pts received prior antibiotics, and 595 (30%) concurrent. Pathogens were isolated from 836 (42%) pts, most commonly MRSA, 434 (22%). LOC for ABSSSI pts was in general hospital ward (GHW), 1803/1982 (91%), ICU, 156/1982 (8%), and outpatient/home, 23/1982 (1%). Among CABP pts mean age was 63 ± 18 years; 401 (49%) were male; 659 (81%) had comorbidities, most commonly structural lung disease 347 (43%) and smoking 308 (38%). 672 (83%) pts received prior antibiotics, and 520 (64%) concurrent. Pathogens were isolated in 251 (31%) pts, most commonly MRSA, 115 (14%). LOC for CABP pts was in GHW 534/811 (66%) and ICU 275/811 (34%). See table for clinical success by LOC.

    Conclusion: Clinical success with CPT-F was favorable in pts with ABSSSI or CABP, in both GHW and ICU.

    Clinical success rates

    ABSSSI

    CABP

    GHW
    n/N (%)

    ICU
    n/N (%)

    GHW
    n/N (%)

    ICU
    n/N (%)

    Overall

    1626/1803 (90)

    123/156 (79)

    479/534 (90)

    205/275 (75)

    ≥1 Comorbidities

    795/891 (89)

    80/103 (78)

    390/433 (90)

    169/224 (75)

    Diabetes

    695/781 (89)

    68/88 (77)

    N/A

    N/A

    PVD

    202/242 (83)

    26/37 (70)

    N/A

    N/A

    Structural lung disease

    N/A

    N/A

    210/233 (90)

    87/113 (77)

    Smoking

    N/A

    N/A

    184/203 (91)

    86/104 (83)

    N/A = not applicable

     

     

     

     

    Keith Kaye, MD, MPH, FIDSA, FSHEA, Detroit Medical Center/Wayne State University, Detroit, MI, George Udeani, PharmD, DSc, FCP, FCCP, Corpus Christi Medical Center, Corpus Christi, TX, Leonard B Johnson, MD, FIDSA, St John Hospital and Medical Center, Grosse Pointe Woods, MI and Chad M Cannon, MD, University of Kansas Hospital, Kansas City, KS

    Disclosures:

    K. Kaye, Actavis: Consultant , Investigator and Speaker's Bureau , Consulting fee , Research grant and Speaker honorarium

    G. Udeani, Forest: Consultant and Investigator , Consulting fee and Research grant

    L. B. Johnson, None

    C. M. Cannon, Actavis: Investigator and Speaker's Bureau , Research support and Speaker honorarium

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.